Aqneursa

News

Shionogi's diversification continues with $2bn IntraBio buy

Shionogi has reached a $2bn agreement to buy Anglo-US biotech IntraBio and its recently approved Aqneursa therapy for two rare genetic disorders.

News

Lilly's appeal unlocks EU approval of Alzheimer's drug

Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy Kisunla has paid off.

News

Second Niemann-Pick approval brings more hope to patients

In the space of four days, the number of FDA-approved therapies for ultra-rare genetic disorder Niemann-Pick disease has gone from zero to two, transforming the prospects for patients.

Shionogi's diversification continues with $2bn IntraBio buy

Lilly's appeal unlocks EU approval of Alzheimer's drug

Second Niemann-Pick approval brings more hope to patients

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks